Peter J. Weiden, MD

  • 38Articles
  • 170.2KReads
  • 1997–2025Active
  • 113Collaborators
  • 1.1KCitations

About

Peter J. Weiden, MD, is affiliated with the Department of Psychiatry and Behavioral Health at the Renaissance School of Medicine at Stony Brook University. With a publication record spanning from 1997 to 2025 and 38 articles, Dr. Weiden has focused on schizophrenia, schizoaffective disorders, bipolar disorder, psychotic disorders, metabolic disorders, neurology, psychiatry, and patient care. His work includes studies on antipsychotic treatments such as aripiprazole lauroxil and the xanomeline-trospium combination, medication adherence, long-acting injectable therapies, and treatment resistance in schizophrenia. He has frequently collaborated with authors including Daniel Carpenter, John P. Docherty, Ruth Ross, John M. Kane, and Joseph P. McEvoy.

Publications

JCP
What Clinicians Should Know About the Pragmatic Use of Xanomeline-Trospium Combination
ASCP Corner

What Clinicians Should Know About the Pragmatic Use of Xanomeline-Trospium Combination

June 9, 2025

This article will help familiarize clinicians with practical issues in the use of xanomeline-trospium and its entry into the pharmacopoeia for schizophrenia.
,
JCP
Aripiprazole Lauroxil Initiation Regimens
Original Research

Aripiprazole Lauroxil Initiation Regimens

August 12, 2024

In separate studies of the two initiation methods, the numbers of people who had side effects were similar, and most side effects were mild.
, , , et al
JCP
Antipsychotic Efficacy of KarXT (Xanomeline−Trospium)
Original Research

Antipsychotic Efficacy of KarXT (Xanomeline−Trospium)

image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ May 11, 2022

This post hoc analysis of phase 2 data evaluated rates and time course of response with the new combination oral agent KarXT (xanomeline−trospium) in the treatment of schizophrenia.
, , , et al
JCP
Original Research

Long-Term Safety of Aripiprazole Lauroxil

August 18, 2020

Long-acting injectable (LAI) antipsychotics improve adherence, reduce treatment gaps, and improve clinical outcomes. This report describes the long-term safety, tolerability, and symptom trajectory with the LAI antipsychotic aripiprazole lauroxil.
, , , et al
JCP
Original Research

Aripiprazole Lauroxil to Treat Schizophrenia

May 19, 2020

Read a study examining the efficacy and tolerability of the long-acting injectable (LAI) aripiprazole lauroxil from inpatient into follow-up outpatient care.
, , , et al
JCP
Original Research

Therapeutic Durability of Aripiprazole Lauroxil

September 19, 2017

Injectable antipsychotics can help address the problem of nonadherence, which can lead to relapse. This study looks at the efficacy of the injectable antipsychotic aripiprazole lauroxil in achieving and...
, , , et al
JCP
Original Research

Half-Life After Antipsychotic Discontinuation

August 23, 2017

Read the results on whether a longer half-life is associated with longer time to relapse after antipsychotic discontinuation, even among LAI formulations.
, , , et al
JCP
Original Research

Expert Consensus Survey: Adherence and Digital Medicine

August 23, 2017

What are the primary causes of poor patient outcomes in psychiatry, and what can be done to address these? A panel of 58 experts in psychiatry completed a survey...
, , , et al
JCP
Commentary

How Many Treatments Before Clozapine? Medication Choices Across the Spectrum of Treatment Resistance in Schizophrenia

May 25, 2016

JCP
Original Research

The Challenge of Offering Long-Acting Antipsychotic Therapies: A Preliminary Discourse Analysis of Psychiatrist Recommendations for Injectable Therapy to Patients With Schizophrenia

June 24, 2015

, , , et al
JCP
Academic Highlights

Switching Antipsychotic Medications to Reduce Adverse Event Burden in Schizophrenia: Establishing Evidence-Based Practice

October 23, 2013

, ,
JCP
Original Research

Efficacy and Effectiveness of Depot Versus Oral Antipsychotics in Schizophrenia: Synthesizing Results Across Different Research Designs

April 19, 2013

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Ketamine and Psychedelics

Listen to the Podcast
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe